2017 American Transplant Congress
Alemtuzumab Induction Is Safe, and Permits the Avoidance of Steroids in the Majority of Renal Transplant Recipients.
IntroductionThe introduction of alemtuzumab into routine clinical use has been hindered by safety concerns surrounding its prolonged effect on the lymphoid compartment. Here we report…2017 American Transplant Congress
Benefits of Induction in Recipients of Acute Renal Failure Donor Kidneys.
University of Michigan, Ann Arbor
Kidneys from donors with acute renal failure (ARF) are often discarded due to concerns for DGF and graft failure. Induction immunosuppression can be used to…2017 American Transplant Congress
National Variation in US Kidney Transplant Induction Therapy.
Antibody induction (IND) therapy in kidney transplantation (KTx) reduces acute rejection risk but adds to transplant cost. Currently, only IL2 Receptor antibodies (IL2R-Ab) have FDA…2017 American Transplant Congress
Reassessing Thymoglobulin Induction in Kidney Transplantation (RETHINK): An Analysis of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) Registry.
There is no consensus on Thymoglobulin (TMG) dose used for induction immunosuppression (IS) in pediatric kidney transplants (KTx). We aimed to identify: 1) TMG induction…2017 American Transplant Congress
Induction Immunotherapy in ECD and DGF Kidneys: Does ECD Equal Diminishing Induction Returns?
University of Michigan, Ann Arbor
The benefit of induction immunotherapy to prevent DGF or mitigate its effects in recipients of marginal kidneys is not well understood and practices vary. We…2017 American Transplant Congress
Induction Therapy in Low Risk Elderly Kidney Transplant Recipients: Donor Factors.
Johns Hopkins, Baltimore; University of Colorado, Denver
It is not known whether depleting induction is needed in low-risk elderly kidney transplant (KT) recipients in whom concern for infectious and complications is higher…2017 American Transplant Congress
Prospective Randomized Study to Evaluate the Efficacy and Safety of Rabbit Antithymocyte Globulin (rATG) 3mg/kg vs. 6mg/kg in Kidney Transplant Patients Under Steroid-Free and CNI Minimization Maintenance Immunosuppressive Regimen.
Hospital Geral de Fortaleza, Fortaleza, Brazil
Background: rATG dosed from 4.5 to 7.5mg/kg has been the standard of care in most transplant centers. Recent studies have demonstrated similar efficacy with doses…2017 American Transplant Congress
Five Year Outcomes with Alemtuzumab Induction Therapy in Elderly Renal Transplant Recipients.
Pharmacy, Northwestern Memorial Hospital, Chicago, IL
Background:The elderly population (≥ 65 years) comprise one fourth of patients on the waiting list for renal transplantation. Alemtuzumab use has increased over the past…2017 American Transplant Congress
Induction in the Elderly: A Comparison of Basiliximab versus Rabbit Anti-Thymocyte Globulin After Kidney Transplantation.
Weill Cornell Medical Center, New York, NY
Background: Although it is well established that kidney transplant (KT) in the elderly is beneficial and safe, there is limited literature on the appropriate choice…2017 American Transplant Congress
Impact of Alemtuzumab Induction on Hepatitis C Treatment Outcomes Post-Renal Transplantation.
University of Maryland Medical Center, Baltimore, MD
BackgroundDirect-acting antiviral agents (DAAs) have improved treatment outcomes for Hepatitis C virus (HCV). Given high rates of treatment success with few side effects, eradication of…
- « Previous Page
- 1
- …
- 19
- 20
- 21
- 22
- 23
- …
- 31
- Next Page »